Antidepressant Treatment Can Normalize Adult Behavioral Deficits Induced by Early-Life Exposure to Methylphenidate

Biological Psychiatry

Volumn 63, Issue 3, 2008, Pages 309-316

  Bolaños, Carlos A ^a   Willey, Matthew D ^a   Maffeo, Melissa L ^a   Powers, Kyle D ^a   Kinka, Daniel W ^a   Grausam, Katie B ^a   Henderson, Ross P ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Adolescence; antidepressant treatment; development; emotion; fluoxetine; methylphenidate; morphine; rat

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; METHYLPHENIDATE; MORPHINE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; SUCROSE;

ADOLESCENCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FORCED SWIMMING TEST; GROOMING; MALE; NONHUMAN; PERINATAL PERIOD; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; STRESS; TASK PERFORMANCE;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; FLUOXETINE; FOOD PREFERENCES; MALE; MAZE LEARNING; MENTAL DISORDERS; METHYLPHENIDATE; RATS; RATS, SPRAGUE-DAWLEY; SWIMMING;

EID: 37849030653     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.06.024     Document Type: Article

References (82)

1. Findling R.L., and Dogin J.W. Psychopharmacology of ADHD: Children and adolescents. J Clin Psychiatry 59 suppl 7 (1998) 42-49
2. Arnsten A.F. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31 (2006) 2376-2383
3. Miller K.J., and Castellanos F.X. Attention deficit/hyperactivity disorders. Pediatr Rev 19 (1998) 373-384
4. Kirby K., Rutman L.E., and Bernstein H. Attention-deficit/hyperactivity disorder: A therapeutic update. Curr Opin Pediatr 14 (2002) 236-246
5. Zito J.M., Safer D.J., dosReis S., Gardner J.F., Boles M., and Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283 (2000) 1025-1030
6. Teicher M.H., Ito Y., Glod C.A., and Barber N.I. Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psychiatry 35 (1996) 334-342
7. Nass R.D. Evaluation and assessment issues in the diagnosis of attention deficit hyperactivity disorder. Semin Pediatr Neurol 12 (2005) 200-216
8. Rey J.M., and Sawyer M.G. Are psychostimulant drugs being used appropriately to treat child and adolescent disorders?. Br J Psychiatry 182 (2003) 284-286
9. Poulin C. Medical and nonmedical stimulant use among adolescents: From sanctioned to unsanctioned use. CMAJ 165 (2001) 1039-1044
10. Jensen P.S., Kettle L., Roper M.T., Sloan M.T., Dulcan M.K., Hoven C., et al. Are stimulants overprescribed?. Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry 38 (1999) 797-804
11. Silver L.B. Attention-deficit/hyperactivity disorder in adult life. Child Adolesc Psychiatr Clin N Am 9 (2000) 511-523
12. Spencer T., Biederman J., Wilens T., Harding M., O'Donnell D., and Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35 (1996) 409-432
13. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
14. Wise R.A., and Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Rev 94 (1987) 469-492
15. Schweri M.M., Skolnick P., Rafferty M.F., Rice K.C., Janowsky A.J., and Paul S.M. [3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: Correlation with the stimulant properties of ritalinic acid esters. J Neurochem 45 (1985) 1062-1070
16. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. J Neurochem 68 (1997) 2032-2037
17. Gerasimov M.R., Franceschi M., Volkow N.D., Rice O., Schiffer W.K., and Dewey S.L. Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38 (2000) 432-437
18. Yang P.B., Swann A.C., and Dafny N. Chronic methylphenidate modulates locomotor activity and sensory evoked responses in the VTA and NAc of freely behaving rats. Neuropharmacology 51 (2006) 546-556
19. McDougall S.A., Collins R.L., Karper P.E., Watson J.B., and Crawford C.A. Effects of repeated methylphenidate treatment in the young rat: Sensitization of both locomotor activity and stereotyped sniffing. Exp Clin Psychopharmacol 7 (1999) 208-218
20. Carlezon Jr. W.A., and Nestler E.J. Elevated levels of GluR1 in the midbrain: A trigger for sensitization to drugs of abuse?. Trends Neurosci 25 (2002) 610-615
21. Biederman J., Wilens T., Mick E., Faraone S.V., Weber W., Curtis S., et al. Is ADHD a risk factor for psychoactive substance use disorders?. Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 36 (1997) 21-29
22. Kollins S.H., MacDonald E.K., and Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68 (2001) 611-627
23. Wilens T.E., Faraone S.V., Biederman J., and Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse?. A meta-analytic review of the literature. Pediatrics 111 (2003) 179-185
24. Mannuzza S., Klein R.G., and Moulton III J.L. Does stimulant treatment place children at risk for adult substance abuse?. A controlled, prospective follow-up study. J Child Adolesc Psychopharmacol 13 (2003) 273-282
25. Andersen S.L., Arvanitogiannis A., Pliakas A.M., LeBlanc C., and Carlezon Jr. W.A. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 5 (2002) 13-14
26. Achat-Mendes C., Anderson K.L., and Itzhak Y. Methylphenidate and MDMA adolescent exposure in mice: Long-lasting consequences on cocaine-induced reward and psychomotor stimulation in adulthood. Neuropharmacology 45 (2003) 106-115
27. Carlezon Jr. W.A., Mague S.D., and Andersen S.L. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 54 (2003) 1330-1337
28. Bolaños C.A., Barrot M., Berton O., Wallace-Black D., and Nestler E.J. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol Psychiatry 54 (2003) 1317-1329
29. Angold A., Erkanli A., Egger H.L., and Costello E.J. Stimulant treatment for children: A community perspective. J Am Acad Child Adolesc Psychiatry 39 (2000) 975-984 discussion 984-994
30. Andersen S.L., and Navalta C.P. Altering the course of neurodevelopment: A framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci 22 (2004) 423-440
31. Gualtieri C.T., Wargin W., Kanoy R., Patrick K., Shen C.D., Youngblood W., et al. Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry 21 (1982) 19-26
32. Kuczenski R., and Segal D.S. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol Psychiatry 57 (2005) 1391-1396
33. Willner P., Towell A., Sampson D., Sophokleous S., and Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93 (1987) 358-364
34. Hoffman D.C. The use of place conditioning in studying the neuropharmacology of drug reinforcement. Brain Res Bull 23 (1989) 373-387
35. Carlezon Jr. W.A. Place conditioning to study drug reward and aversion. Methods Mol Med 84 (2003) 243-249
36. Spruijt B.M., Welbergen P., Brakkee J., and Gispen W.H. An ethological analysis of excessive grooming in young and aged rats. Ann N Y Acad Sci 525 (1988) 89-100
37. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci 23 (2002) 238-245
38. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8 (1997) 523-532
39. Mague S.D., Andersen S.L., and Carlezon Jr. W.A. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry 57 (2005) 120-125
40. Robbins T.W., and Everitt B.J. Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6 (1996) 228-236
41. Kelley A.E., and Berridge K.C. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22 (2002) 3306-3311
42. Shimura T., Kamada Y., and Yamamoto T. Ventral tegmental lesions reduce overconsumption of normally preferred taste fluid in rats. Behav Brain Res 134 (2002) 123-130
43. Hajnal A., and Norgren R. Accumbens dopamine mechanisms in sucrose intake. Brain Res 904 (2001) 76-84
44. Datla K.P., Ahier R.G., Young A.M., Gray J.A., and Joseph M.H. Conditioned appetitive stimulus increases extracellular dopamine in the nucleus accumbens of the rat. Eur J Neurosci 16 (2002) 1987-1993
45. Brandon C.L., Marinelli M., Baker L.K., and White F.J. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 25 (2001) 651-661
46. Brandon C.L., Marinelli M., and White F.J. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biol Psychiatry 54 (2003) 1338-1344
47. Crawford C.A., Villafranca S.W., Cyr M.C., Farley C.M., Reichel C.M., Gheorghe S.L., et al. Effects of early methylphenidate exposure on morphine- and sucrose-reinforced behaviors in adult rats: Relationship to dopamine D2 receptors. Brain Res 1139 (2007) 245-253
48. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24 (2000) 417-463
49. Zavala A.R., Yoshida S.T., Osburn J.R., and McDougall S.A. Paradoxical locomotor activating effects of kappa-opioid receptor stimulation in the preweanling rat: Role of the ventromedial thalamus and superior colliculus. Brain Res Dev Brain Res 139 (2002) 301-306
50. Bolaños C.A., Glatt S.J., and Jackson D. Subsensitivity to dopaminergic drugs in periadolescent rats: A behavioral and neurochemical analysis. Brain Res Dev Brain Res 111 (1998) 25-33
51. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology (Berl) 134 (1997) 319-329
52. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59 (2006) 1151-1159
53. Di Chiara G., Loddo P., and Tanda G. Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: Implications for the psychobiology of depression. Biol Psychiatry 46 (1999) 1624-1633
54. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311 (2006) 864-868
55. Sanchez C., Gruca P., and Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14 (2003) 465-470
56. Rygula R., Abumaria N., Domenici E., Hiemke C., and Fuchs E. Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats. Behav Brain Res 174 (2006) 188-192
57. de Montigny C., and Blier P. Effects of antidepressant treatments on 5-HT neurotransmission: electrophysiological and clinical studies. Adv Biochem Psychopharmacol 39 (1984) 223-239
58. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
59. To C.T., Anheuer Z.E., and Bagdy G. Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety. Neuroreport 10 (1999) 553-555
60. Grippo A.J., Beltz T.G., Weiss R.M., and Johnson A.K. The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiatry 59 (2006) 309-316
61. Cryan J.F., Page M.E., and Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 182 (2005) 335-344
62. Manji H.K., Drevets W.C., and Charney D.S. The cellular neurobiology of depression. Nat Med 7 (2001) 541-547
63. Sekine Y., Suzuki K., Ramachandran P.V., Blackburn T.P., and Ashby Jr. C.R. Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse 61 (2007) 72-77
64. Serra G., Collu M., D'Aquila P.S., and Gessa G.L. Role of the mesolimbic dopamine system in the mechanism of action of antidepressants. Pharmacol Toxicol 71 suppl 1 (1992) 72-85
65. Bolaños C.A., Trksak G.H., Cohen O.S., and Jackson D. Differential serotonergic inhibition of in vitro striatal [3H]acetylcholine release in prenatally cocaine-exposed male and female rats. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 1339-1348
66. Bolaños C.A., Trksak G.H., Glatt S.J., and Jackson D. Prenatal cocaine exposure increases serotonergic inhibition of electrically evoked acetylcholine release from rat striatal slices at adulthood. Synapse 36 (2000) 1-11
67. Deslandes P.N., Pache D.M., Buckland P., and Sewell R.D. Morphine, cocaine and antidepressant induced motivational activity and midbrain dopaminergic neurotransmission. Eur J Pharmacol 453 (2002) 223-229
68. Nomikos G.G., Damsma G., Wenkstern D., and Fibiger H.C. Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens. Eur J Pharmacol 195 (1991) 63-73
69. Laasonen-Balk T., Kuikka J., Viinamaki H., Husso-Saastamoinen M., Lehtonen J., and Tiihonen J. Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 144 (1999) 282-285
70. Gispen W.H., Colbern D.L., and Spruijt B.M. Molecular transduction mechanisms in ACTH-induced grooming. Psychopharmacol Ser 4 (1988) 215-231
71. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: A new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
72. den Boer J.A., Westenberg H.G., Kamerbeek W.D., Verhoeven W.M., and Kahn R.S. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 2 (1987) 21-32
73. Papp L.A., Sinha S.S., Martinez J.M., Coplan J.D., Amchin J., and Gorman J.M. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 34 (1998) 207-209
74. Nutt D.J., Glue P., and Lawson C. The neurochemistry of anxiety: An update. Prog Neuropsychopharmacol Biol Psychiatry 14 (1990) 737-752
75. Bagdy G., Graf M., Anheuer Z.E., Modos E.A., and Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4 (2001) 399-408
76. Belzung C., Le Guisquet A.M., Barreau S., and Calatayud F. An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. Behav Pharmacol 12 (2001) 151-162
77. Drapier D., Bentue-Ferrer D., Laviolle B., Millet B., Allain H., Bourin M., et al. Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze. Behav Brain Res 176 (2007) 202-209
78. Silva R.C., and Brandao M.L. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: An ethological analysis. Pharmacol Biochem Behav 65 (2000) 209-216
79. Carlezon Jr. W.A., and Konradi C. Understanding the neurobiological consequences of early exposure to psychotropic drugs: Linking behavior with molecules. Neuropharmacology 47 suppl 1 (2004) 47-60
80. Lagace D.C., Yee J.K., Bolanos C.A., and Eisch A.J. Juvenile administration of methylphenidate attenuates adult hippocampal neurogenesis. Biol Psychiatry 60 (2006) 1121-1130
81. Barrot M., Olivier J.D., Perrotti L.I., DiLeone R.J., Berton O., Eisch A.J., et al. CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. Proc Natl Acad Sci U S A 99 (2002) 11435-11440
82. Pliakas A.M., Carlson R.R., Neve R.L., Konradi C., Nestler E.J., and Carlezon Jr. W.A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci 21 (2001) 7397-7403